research Treatment of Lipodystrophy with Troglitazone
Troglitazone increases subcutaneous fat in lipodystrophy patients.
Search
for
Sort by
Research
630-660 / 1000+ results research Atopic Dermatitis and Multilocular Alopecia Areata Simultaneously Treated With Baricitinib
Baricitinib effectively improved both atopic dermatitis and alopecia areata symptoms in a patient.
research 15460 Perifollicular pink halo: A potential dermoscopic marker of inflammation in central centrifugal cicatricial alopecia
Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
research 696 MEK and BRAF inhibitors augment the production and accumulation of sebum in hamster sebocytes
MEK and BRAF inhibitors increase sebum production and accumulation, which could cause acne-like side effects.
research Activation of AR Sensitizes Breast Carcinomas to NVP-BEZ235's Therapeutic Effect Mediated by PTEN and KLLN Upregulation
Breast cancer treatments work better with AR activation, improving results and reducing side effects.
research Repigmentation of hair following adalimumab therapy
A patient's grey hair regained color during treatment with adalimumab.
research Hair Depigmentation Is a Biological Readout for Pharmacological Inhibition of KIT in Mice and Humans
Hair color loss can indicate the effectiveness of a drug targeting the KIT protein in mice and humans.
research Sinapic acid and glabridin synergistically mitigate androgenetic alopecia by modulating ferroptosis through stabilization of β-catenin against ubiquitin-dependent degradation.
Sinapic acid and glabridin together help hair growth in androgenetic alopecia.
research Supplemental Material: Tolerability and Efficacy of Unorthodox Dosing Regimens of Tofacitinib and Baricitinib in Pediatric Patients with Moderate to Severe Alopecia Areata
Unorthodox dosing of tofacitinib and baricitinib is safe but less effective than standard dosing for treating alopecia areata in kids.
research Target-Adverse Events and Fear of Cancer Progression, Anxiety, and Depression in Patients with Advanced Non-Small Cell Lung Cancer
Adverse events in lung cancer treatments increase fear, anxiety, and depression, with newer therapies causing fewer side effects.
research Alopecia Areata: Case report and review of pathophysiology and treatment with Jak inhibitors
JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.
research Disruption of tubular Flcn expression as a mouse model for renal tumor induction
Disrupting the Flcn gene in mice causes early kidney cysts and tumors, which can be treated with rapamycin.
research Use of oral Janus kinase inhibitors for the treatment of severe alopecia areata: narrative review and real-world experience
Janus kinase inhibitors help some people with severe alopecia areata regrow hair, but not everyone responds, and relapses can happen.
research 26143 Time to scalp hair, eyebrow, and eyelash improvement in patients with alopecia areata treated with baricitinib in the phase 2 portion of the phase 2/3 BRAVE-AA1 study
Baricitinib helped improve hair, eyebrow, and eyelash growth in alopecia areata patients.
research Excessive hair growth around local β‐interferon injection sites for malignant melanoma
β-interferon injections for melanoma can cause excessive hair growth at the injection sites.
research Efficacy and safety of ritlecitinib, an oral JAK3 /TEC family kinase inhibitor, in adolescent and adult patients with alopecia totalis and alopecia universalis
Ritlecitinib helps regrow hair in people with alopecia totalis and universalis and is safe to use.
research 598 Response to ritlecitinib treatment based on salt improvement scores in patients with alopecia areata (AA): Post hoc analysis of the allegro phase 2b/3 study
Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
research Gfp-Expressing Vascularization of Gelfoam® as a Rapid in Vivo Assay of Angiogenesis Stimulators and Inhibitors
The assay quickly identifies substances that increase or decrease blood vessel growth.
research Effectiveness and safety of baricitinib in patients with moderate‐to‐severe refractory alopecia areata in real world: An open‐label, single‐center study
Baricitinib effectively and safely improves hair growth in patients with severe alopecia areata.
research LB1056 Phase 1b: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo
VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.
research JAK Inhibitors in African American Patients With Alopecia Areata: A Case Series
JAK inhibitors effectively reduce alopecia areata symptoms in Black patients.
research Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study
Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.
research Baricitinib Treatment Increases Eyebrow and Eyelash Regrowth Up to 52 Weeks
research Kinetic analysis of LY320236: competitive inhibitor of type I and non-competitive inhibitor of type II human steroid 5α-reductase
LY320236 is a strong blocker of two enzymes that change testosterone into dihydrotestosterone and might help treat conditions related to male hormones.
research SnapshotDx Quiz: March 2016
JAK inhibitors may help treat alopecia areata by reversing hair loss.
research Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
Ritlecitinib is an effective new treatment for Alopecia Areata.
research Fabrication and in vitro evaluation of silk fibroin-folic acid decorated paclitaxel and hydroxyurea nanostructured lipid carriers for targeting ovarian cancer cells: A double sword approach
The new drug carriers show promise for better targeting and treating ovarian cancer.
research Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
Continued ritlecitinib treatment can improve hair regrowth in some alopecia areata patients who initially don't respond.
research The development of oral hairy leukoplakia during JAK inhibitor baricitinib therapy
A man developed oral hairy leukoplakia while on baricitinib, a medication for alopecia and arthritis, and doctors should watch for such side effects.
research Tufted hair folliculitis in a woman treated with trastuzumab
Trastuzumab may cause tufted hair folliculitis as a side effect.